De nouvelles molécules pour les infections fongiques ?

Among the new classes of antifungal drugs, FG3409, a “small molecule”, has been investigated. FG3409 has a wide spectrum, including species and isolates resistant to azoles or amphotericin B. Pharmacological studies in vitro and in animal models show a good safety and an efficacy in the same range as itraconazole and caspofungin. FG3409 has a good pharmacokinetic profile, with both oral and i.v. routes available, and few drug interactions. Another strategy is the concomitant use of human monoclonal antibody against Heat Shock Protein 90 (HSP90) and liposomal amphotericin B. Despite a promising clinical trial, development on this strategy seems to slow down.